Refractory Dravet is a 1,400 to 2,000-patient US market, and the clinical bar is over 40% additional seizure reduction beyond CBD plus fenfluramine.

Cannabidiol (Epidiolex, Jazz Pharmaceuticals, approved 2018) is the dominant Dravet standard of care, holding 55-60% of the Dravet-specific market on a six-year track record of physician loyalty and a WAC near $32,000 a year once patient-assistance support is applied. Fenfluramine (Fintepla, UCB, approved 2020) has taken 25-30% share on a stronger responder rate, 62% seizure reduction in STUDIO 1 versus 38.9% for cannabidiol in GWPCARE1-4, but carries a REMS requirement of baseline, 3-month, 6-month and then twice-yearly echocardiography. An estimated 20-30% of eligible US Dravet patients cannot access fenfluramine because community paediatric neurology practices lack echo capacity, making REMS-free cardiac safety a structural access advantage for any new entrant.

Even with both drugs available, 35-40% of US Dravet patients, an estimated 1,400-2,000, remain inadequately controlled, less than 50% seizure reduction, on cannabidiol plus fenfluramine. This refractory cohort is the pre-launch target population: SCN1A-confirmed, typically still experiencing more than 20 seizures a month, and carrying a lifetime SUDEP risk of 2-18% that translates to an estimated 40-80 US Dravet deaths annually. Comorbidity burden is high, with intellectual disability in 70-80%, autism-spectrum features in 20-30%, and gait abnormalities in 70%. Caregiver burden averages 60-plus hours a week, evidence that FDA and payers increasingly expect alongside seizure-frequency data in trial design.

Refractory patients face a 2 to 18% lifetime SUDEP risk despite two approved therapies.

Five questions this report answers:

Q1 - What clinical bar must a new Dravet agent clear against cannabidiol and fenfluramine?

Q2 - How large is the refractory Dravet cohort, and how is it identified pre-approval?

Q3 - What PA criteria and Medicaid groundwork does a new Dravet agent need before approval?

Q4 - What deliverable formats come with a commissioned Dravet launch readiness assessment?

Q5 - What must a new Dravet Syndrome agent prove and prepare before a US launch?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #Epilepsy #RareDisease #USMarketAccess #LaunchReadiness #PediatricNeurology

Live report page:  https://axlrx.ai/dravet-syndrome/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/